SNDX - Syndax Pharmaceuticals Inc

QQQ $ 612.11 $ 7.61 (1.26 %)

DIA $ 467.12 $ 5.24 (1.13 %)

SPY $ 671.75 $ 6.91 (1.04 %)

TLT $ 91.68 $ 0.35 (0.38 %)

GLD $ 401.36 $ 14.16 (3.64 %)

Previous Close

$ 15.57

Open

$ 14.56

Bid

$ 15.36 x 330

Ask

$ 15.99 x 13

Day's Range

$ 14.54 - $ 15.78

52 Week Range

$ 8.58 - $ 22.50

Volume

5,077,396

Average Volume

Market Cap

1.34B

Beta (5Y Monthly)

$ 0.86

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-04-2025	06-30-2025	10-Q
2	05-05-2025	03-31-2025	10-Q
3	03-03-2025	01-01-1970	10-K
4	11-05-2024	09-30-2024	10-Q
5	08-01-2024	06-30-2024	10-Q
6	05-08-2024	03-31-2024	10-Q
7	02-27-2024	12-31-2023	10-K
8	11-02-2023	09-30-2023	10-Q
9	08-03-2023	06-30-2023	10-Q
10	05-08-2023	03-31-2023	10-Q
11	02-28-2023	12-31-2022	10-K
12	11-03-2022	09-30-2022	10-Q
13	08-08-2022	06-30-2022	10-Q
14	05-09-2022	03-31-2022	10-Q
15	03-01-2022	12-31-2021	10-K
16	11-15-2021	09-30-2021	10-Q
17	08-09-2021	06-30-2021	10-Q
18	05-11-2021	03-31-2021	10-Q
19	03-12-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q
21	08-06-2020	06-30-2020	10-Q
22	05-07-2020	03-31-2020	10-Q
23	03-05-2020	12-31-2019	10-K
24	11-07-2019	09-30-2019	10-Q
25	08-07-2019	06-30-2019	10-Q
26	05-08-2019	03-31-2019	10-Q
27	03-07-2019	12-31-2018	10-K
28	11-05-2018	09-30-2018	10-Q
29	08-08-2018	06-30-2018	10-Q
30	05-09-2018	03-31-2018	10-Q
31	03-08-2018	12-31-2017	10-K
32	11-08-2017	09-30-2017	10-Q
33	08-10-2017	06-30-2017	10-Q
34	05-09-2017	03-31-2017	10-Q
35	03-14-2017	12-31-2016	10-K
36	11-14-2016	09-30-2016	10-Q
37	08-15-2016	06-30-2016	10-Q
38	05-16-2016	03-31-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Where Syndax Pharmaceuticals Stands With A...
10/16/2025 14:02:42

HC Wainwright & Co. Assumes Syndax Pharmac...
10/16/2025 10:49:31

HC Wainwright & Co. analyst Andres Y. Maldonado assumes Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and annou...

BTIG Reiterates Buy on Syndax Pharmaceutic...
09/19/2025 17:11:10

BTIG analyst Justin Zelin reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $56 price target.

$syndaxs-revuforj-revumenib-added-to-nccn-guidelines-as-category-2a-treatment-for-relapsedrefractory-npm1-mutated-aml-supported-by-augment-101-trial-fda-priority-review-snda-decision-due-oct-25-2025$

Syndax's Revuforj (Revumenib) Added To NCC...
09/19/2025 11:02:18

Stifel Reinstates Buy on Syndax Pharmaceut...
09/10/2025 12:33:48

Stifel analyst Bradley Canino reinstates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and announces $44 price target.

Goldman Sachs Maintains Buy on Syndax Phar...
09/05/2025 14:52:24

Goldman Sachs analyst Corinne Johnson maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target ...

syndax-gains-attention-with-strong-drug-portfolio-path-to-leukemia-market-growth

Syndax Gains Attention With Strong Drug Po...
09/04/2025 19:17:43

Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term pro...

this-hubspot-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

This HubSpot Analyst Begins Coverage On A ...
09/04/2025 14:14:40

Deep Dive Into Syndax Pharmaceuticals Stoc...
09/04/2025 12:02:06

Guggenheim Initiates Coverage On Syndax Ph...
09/04/2025 11:43:20

Guggenheim analyst Bradley Canino initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and announces...

Citigroup Maintains Buy on Syndax Pharmace...
08/05/2025 17:59:42

Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target fr...

BTIG Maintains Buy on Syndax Pharmaceutica...
08/05/2025 16:29:27

BTIG analyst Justin Zelin maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $43 to ...

Syndax Pharmaceuticals Q2 EPS $(0.83) Beat...
08/04/2025 20:04:32

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate o...

Earnings Scheduled For August 4, 2025
08/04/2025 08:32:29

Syndax Pharmaceuticals's Earnings: A Preview
08/01/2025 21:04:30

UBS Maintains Buy on Syndax Pharmaceutical...
07/15/2025 14:46:04

UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $37 to $35.

Goldman Sachs Initiates Coverage On Syndax...
07/10/2025 12:51:24

Goldman Sachs analyst Corinne Johnson initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and annou...

$syndax-pharmaceuticals-announces-that-the-fda-has-granted-priority-review-for-its-supplemental-new-drug-application-for-revuforj-in-relapsed-or-refractory-mnpm1-acute-myeloid-leukemia$

Syndax Pharmaceuticals Announces That The ...
06/24/2025 20:03:28

PDUFA action date set for October 25, 2025 –– sNDA being reviewed under FDA's RTOR program –– Revumenib has the potential ...

Syndax's Revumenib Granted FDA Priority Re...
06/24/2025 20:02:20

– PDUFA action date set for October 25, 2025 –– sNDA being reviewed under FDA's RTOR program –– Revumenib has the potential...

Syndax's Revumenib Shows 67% CR, 88% ORR, ...
06/12/2025 16:07:33

– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar ...